Malaria DNA vaccine demonstrates robust immune responses in animal models

Inovio Pharmaceuticals, Inc. have announced that its SynCon DNA vaccine containing multiple malaria antigens delivered via its CELLECTRA electroporation device demonstrated strong and durable antibody and T-cell immune responses in small animals and non-human primates.

http://www.medilexicon.com/medicalnews.php?newsid=264899